The shares of Bausch Health Companies Inc. (NYSE:BHC) has been pegged with a rating of Outperform by Wolfe Research in its latest research note that was published on July 19th, 2019. Wolfe Research wasn’t the only research firm that published a report of Bausch Health Companies Inc., with other equities research analysts also giving their opinion on the stock. Barclays advised investors in its research note published on June 11th, 2019, to Overweight the BHC stock while also putting a $28 price target. The stock had earned Neutral rating from JP Morgan when it published its report on May 13th, 2019. The stock was given Buy rating by SunTrust in its report released on March 20th, 2019, the day when the price target on the stock was placed at $30. Piper Jaffray was of a view that BHC is Overweight in its latest report on January 2nd, 2019. Morgan Stanley thinks that BHC is worth Overweight rating. This was contained in the firm’s report on November 5th, 2018.
Amongst the analysts that rated the stock, 0 have recommended investors to sell it, 6 believe it has the potential for further growth, thus rating it as Hold while 3 advised investors to purchase the stock. The consensus currently stands at a Hold while its average price target is $30.47. The price of the stock the last time has raised by 31.28% from its Week high price while it is raised higher than its 52-Week low price. A look at the stock’s other technical shows that its 14-day RSI now stands at 40.39.
The shares of the company dipped by -3.17% during the trading session on Tuesday, reaching a low of $21.53 while ending the day at $22.58. During the trading session, a total of 11.03 million shares were traded which represents a -201.25% decline from the average session volume which is 3.66M shares. BHC had ended its last session trading at 23.32. Bausch Health Companies Inc. currently has a market cap of $7.89B while its P/E earnings growth sits at 0.94, with a beta of 0.76. Bausch Health Companies Inc. debt-to-equity ratio currently stands at 8.98, while its quick ratio hovers at 0.80. BHC 52-week low price stands at $17.20 while its 52-week high price is $28.45.
The company in its last quarterly report recorded $1.02 earnings per share which is above the $0.86 predicted by most analysts. The Bausch Health Companies Inc. generated $2,016.00 million in revenue during the last quarter, which is slightly lower than the $2,028.51 million predicted by analysts. In the second quarter last year, the firm recorded $1.03 earnings per share. Compared to the same quarter last year, the firm’s revenue was down by -0.98%. Bausch Health Companies Inc. has the potential to record -4.61 EPS for the current fiscal year, according to equities analysts.
Investment analysts at Citigroup published a research note on July 12th, 2019 where it informed investors and clients that Fifth Third Bancorp (NASDAQ:FITB) is now rated as Neutral. Their price target on the stock stands at $30. Barclays also rated FITB as Resumed on June 11th, 2019, with its price target of $16 suggesting that FITB could surge by 14.3% from its current share price. Even though the stock has been trading at $26.98/share, analysts expect it to surge higher by 1.04% to reach $31.81/share. It started the day trading at $27.78 and traded between $26.69 and $27.26 throughout the trading session.
A look at its technical shows that FITB’s 50-day SMA is 27.81 while its 200-day SMA stands at 26.93. The stock has a high of $30.31 for the year while the low is $22.12. The company’s P/E ratio currently sits at 9.19, while the P/B ratio is 0.98. At the moment, only of Fifth Third Bancorp shares were sold short. The company’s average trading volume currently stands at 6.16M shares, which means that the short-interest ratio is just 1.20 days. Over the past seven days, the company moved, with its shift of -8.77%. Looking further, the stock has dropped -2.92% over the past 90 days while it gained 1.38% over the last six months.
The change in the stock’s fortunes has led to several institutional investors altering their holdings of the stock. T Rowe Price Associates Inc bought more FITB shares, increasing its portfolio by +9.80% during the last quarter. This move now sees T Rowe Price Associates Inc purchasing 6,755,134 shares in the last quarter, thus it now holds 75,686,624 shares of FITB, with a total valuation of $2,111,656,810. The Vanguard Group Inc meanwhile bought more FITB shares in the recently filed quarter, changing its stake to $1,761,203,068 worth of shares. BlackRock Fund Advisors followed the path by decreasing its FITB portfolio by -9.49% in the quarter. This means that BlackRock Fund Advisors sold -3,871,306 shares in the last quarter and now controls 36,942,674 shares of the FITB stock, with the valuation hitting $1,030,700,605.
Similarly, Sanders Capital LLC increased its Fifth Third Bancorp shares by +3.56% during the recently filed quarter. After buying 654,400 shares in the last quarter, the firm now controls 19,052,485 shares of Fifth Third Bancorp which are valued at $531,564,332. In the same vein, Dimensional Fund Advisors LP increased its Fifth Third Bancorp shares by during the most recent reported quarter. The firm bought 2,270,258 shares during the quarter which increased its stakes to 16,903,360 shares and is now valued at $471,603,744. Following these latest developments, around 0.30% of Fifth Third Bancorp stocks are owned by institutional investors and hedge funds.